List of Rexulti drug patents
Rexulti is owned by Otsuka.
Rexulti contains Brexpiprazole.
Rexulti has a total of 6 drug patents out of which 0 drug patents have expired.
Rexulti was authorised for market use on 10 July, 2015.
Rexulti is available in tablet;oral dosage forms.
Rexulti can be used as treatment of schizophrenia; treatment of schizophrenia in adults and pediatric patients ages 13 years and older, adjunctive treatment of major depressive disorder (mdd); treatment of schizophrenia; treatment of schizophrenia in adults and pediatric patients ages 13 years and older, adjunctive treatment of major depressive disorder (mdd).
The generics of Rexulti are possible to be released after 12 October, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7888362 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(2 years from now) | |
| USRE48059 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Dec, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618109 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(2 years from now) | |
| US8349840 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(2 years from now) | |
| US9839637 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(2 years from now) | |
| US10307419 | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Oct, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 27, 2024 |
Drugs and Companies using BREXPIPRAZOLE ingredient
Market Authorisation Date: 10 July, 2015
Treatment: Treatment of schizophrenia; Treatment of schizophrenia in adults and pediatric patients ages 13 years and older; Adjunctive treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
REXULTI family patents
23
United States
8
Japan
3
China
3
Hungary
2
Spain
2
Malaysia
2
India
2
Denmark
2
Poland
2
Brazil
2
Canada
2
Singapore
2
Argentina
2
Korea, Republic of
2
Cyprus
2
Israel
2
Portugal
2
Taiwan
2
Mexico
2
Australia
2
South Africa
2
Lithuania
2
Slovenia
2
European Union
1
Hong Kong
1
Austria
1
Germany
1
Russia
1
Ukraine
1
EA
1
New Zealand
1
Croatia
1
Chile
1
Jordan
1
Netherlands
1
Colombia
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic